TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06747624

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Geranylgeraniol 300 mg
Description: 300 mg of trans-geranylgeraniol (GG)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg medium chain triglycerides
Study: NCT06747065

Intervention type: PROCEDURE
Intervention: Radiotherapy
Description: Radiotherapy post-mastectomy prepectoral implant-based breast reconstruction (IBBR)
Study: NCT05438121

Intervention type: DEVICE
Intervention: SeQuent Please Neo
Description: DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
Study: NCT06376825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyLife: An internet-based self-help program to reduce burnout
Description: MyLife is a internet-based and Acceptance and Commitment Therapy oriented self-help program to reduce burnout. In this study a tailored to teachers version of the program will be used.
Study: NCT05095467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: albumin paclitaxel D1, D8; S-1: D1-D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: albumin paclitaxel D1, D8; S-1: D1-D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: albumin paclitaxel D1, D8; S-1: D1-D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: 40mg bid(BSA\<1.5 m2) ，60mg bid(BSA\>=1.5 m2); D1-D14, po, bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: 40mg bid(BSA\<1.5 m2) ，60mg bid(BSA\>=1.5 m2); D1-D14, po, bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: 40mg bid(BSA\<1.5 m2) ，60mg bid(BSA\>=1.5 m2); D1-D14, po, bid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery+HIPEC
Description: gastrectomy with D2 lymphadenectomy+HIPEC procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery+HIPEC
Description: gastrectomy with D2 lymphadenectomy+HIPEC procedure
Study: NCT06652503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online mental health coaching
Description: SWAG-R Program: A 6-week Coaching Program Designed for NSU Undergraduate Students to Decrease Anxiety, Depression, and Stress and Improve Mental Health, Quality of Life, and Resiliency
Study: NCT05434468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained neutral apophyseal glides
Description: gong mobilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained neutral apophyseal glides
Description: gong mobilization
Study: NCT05891249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days
Study: NCT06660342

Intervention type: DRUG
Intervention: Vonoprazan
Description: Oral tablet.
Study: NCT06662383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Administered SC
Study: NCT06663345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plan Block (TAPB), Lateral Quadratum Lumborum (QLB-1) Block
Description: Following the acquisition of informed consent prior to surgery, 2 mg of intravenous midazolam will be administered to patients who volunteer. These patients will be monitored in the preoperative preparation room. Bilateral TAP or QLB-1 block will be performed, and this block is routinely applied for postoperative pain in our hospital.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plan Block (TAPB), Lateral Quadratum Lumborum (QLB-1) Block
Description: Following the acquisition of informed consent prior to surgery, 2 mg of intravenous midazolam will be administered to patients who volunteer. These patients will be monitored in the preoperative preparation room. Bilateral TAP or QLB-1 block will be performed, and this block is routinely applied for postoperative pain in our hospital.
Study: NCT06608589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers
Description: COMPAS+ is a collaborative approach to improving healthcare quality. It brings together around 30 individuals, including healthcare professionals, deciders, and patient partners, to identify improvement goals, develop action plans, and enhance the prevention and management of chronic diseases. In this study, the investigators adapt COMPAS+ to focus on improving care transitions for patients with major neurocognitive disorders (MNCDs) and their caregivers. Through reflective workshops and collaborative problem-solving, this diverse group will identify best practices and create action plans to enhance care quality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers
Description: COMPAS+ is a collaborative approach to improving healthcare quality. It brings together around 30 individuals, including healthcare professionals, deciders, and patient partners, to identify improvement goals, develop action plans, and enhance the prevention and management of chronic diseases. In this study, the investigators adapt COMPAS+ to focus on improving care transitions for patients with major neurocognitive disorders (MNCDs) and their caregivers. Through reflective workshops and collaborative problem-solving, this diverse group will identify best practices and create action plans to enhance care quality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers
Description: COMPAS+ is a collaborative approach to improving healthcare quality. It brings together around 30 individuals, including healthcare professionals, deciders, and patient partners, to identify improvement goals, develop action plans, and enhance the prevention and management of chronic diseases. In this study, the investigators adapt COMPAS+ to focus on improving care transitions for patients with major neurocognitive disorders (MNCDs) and their caregivers. Through reflective workshops and collaborative problem-solving, this diverse group will identify best practices and create action plans to enhance care quality.
Study: NCT06065345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRight DCB
Description: The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
Study: NCT05534646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotuximab
Description: Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose.
Study: NCT06402825

Intervention type: BEHAVIORAL
Intervention: Fit-for-Fertility program
Description: Women in the intervention group had to delay fertility treatments for 6 months and were offered the interdisciplinary lifestyle intervention, which was provided for a maximum of 18 months or until the end of a pregnancy that occurred. The lifestyle intervention consisted of individual meetings with a dietitian and a kinesiologist trained in motivational interviewing, combined with 12 educational group sessions during the first 6 months. Details of the lifestyle intervention are presented in the previously published protocol (Duval et al., 2015).
Study: NCT05752474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical therapy targeting flexibility, strength, and endurance will be delivered at the participant's home, center-based, or virtually via a twice-weekly (on average) schedule to provide a total of about 6-8 sessions during the 3-4 week study period. Participants will be asked to participate in self-directed exercise for at least 30 minutes per day for 4 or more days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: One-hour virtual group nutrition education classes will be held once per week by a dietitian, focusing on optimal protein intake (1.2 grams per kg of body weight) for lean body mass preservation (from food sources and oral nutritional supplements) and muscle gain. Participants will also receive oral nutritional supplements (20-30 grams of protein/day provided by our study team).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: One-hour virtual group meditation sessions will be held once per week by an experienced meditation teacher. Classes will focus on breathing techniques, yoga, and mindful meditation practices. Participants will be asked to participate in self-directed meditation for at least 12 minutes daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Description: A 30-min telephone-based session with individual patients will take place to deliver cognitive behavioral strategies once per week by a professionally trained clinician. These strategies include education about frailty and surgery, increasing positive beliefs of the benefits of exercise and nutrition, discussing barriers, setting individualized goals for surgery and recovery, developing a detailed exercise and nutrition plan (including logistics), self-monitoring of progress using weekly exercise, diet, and meditation logs, and enhancing self-efficacy through the celebration of small wins.
Study: NCT06542653

Intervention type: PROCEDURE
Intervention: PCI
Description: successful percutaneous coronary intervention (PCI) in Coronary chronic total occlusions (CTOs) patients

Intervention type: DRUG
Intervention: OMT
Description: optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.

Intervention type: DRUG
Intervention: OMT
Description: optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.
Study: NCT06670287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-Sensor Tracking (In-Lab)
Description: In-lab sleep tracking using only raw accelerometer data from a single sensor collected and processed with legacy actigraphy algorithms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Sensor Sleep Tracking (In-Lab)
Description: In-lab sleep tracking using raw accelerometer data and additional sensors collected and processed with machine learning.

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-Sensor Sleep Tracking (At-Home)
Description: At-home sleep tracking using raw accelerometer data and additional sensors collected and processed with machine learning.
Study: NCT06455202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo Subcutaneous Administration
Study: NCT06066736

Intervention type: OTHER
Intervention: observational
Description: No intervention, observational group
Study: NCT05954091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OH2 Injection
Description: OH2 injection will be given intratumorally, and Q2W.
Study: NCT05556330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided autogenous cortical shell technique
Description: computer guided autogenous cortical shell technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: computer guided autogenous cortical shell technique
Description: computer guided autogenous cortical shell technique
Study: NCT06194656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3 Monoclonal antibodies-Dose A
Description: Dose A, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3 Monoclonal antibodies-Dose B
Description: Dose B, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3 Monoclonal antibodies-Dose C
Description: Dose C, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HER3 Monoclonal antibodies-Dose D
Description: The optimal recommended dosage (RP2D) of SIBP-03intravenous, infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SIBP-03 solvent without HER3 antibody, intravenous infusion (IV), once every one weeks, 21 days as a cycle.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab injection
Description: Medications used for combination therapy, intravenous infusion (IV). Administer once a week.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab injection
Description: Medications used for combination therapy, intravenous infusion (IV). Administer once a week.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab injection
Description: Medications used for combination therapy, intravenous infusion (IV). Administer once a week.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab injection
Description: Medications used for combination therapy, intravenous infusion (IV). Administer once a week.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Cetuximab injection
Description: Medications used for combination therapy, intravenous infusion (IV). Administer once a week.
Study: NCT06072924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isotonic Endurance Exercise
Description: Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Exercise
Description: Pressing tongue against pressure sensor at a low threshold (1-15kPa) 30x/day
Study: NCT06681753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: No training will be planned for the Control Group, and their undergraduate education will be included in the study. After the study data is collected and the study is concluded, the control group will be given breastfeeding support training from the intervention group.
Study: NCT05826704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Participants will be taking 2 capsule a day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Participants will be taking 2 capsule a day for 6 weeks
Study: NCT05956600

Intervention type: DRUG
Group type: OTHER
Intervention: Amisulpride 50 MG
Description: Amisulpride 50 mg titrated to dose range of 50 to 1200 mg
Study: NCT06443060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Group
Description: Before starting the Prick procedure, the child in the virtual reality group, which is determined by randomisation, will be given a brief information about how the allergy test will be performed and about virtual reality. Before the Prick test (approximately 2 minutes before the Prick test), the child will start to watch a film deemed appropriate by the experts by wearing virtual reality and headphones. After the child starts watching the film, the child will be asked to extend his/her left arm and solutions will be dripped on the forearm and the puncture will be performed with a lancet. The child will continue to watch the film during the whole procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buzzy Application Group
Description: Before starting the prick procedure, the child in the buzzy group, which was determined by randomisation, will be given a brief information about how the allergy test will be performed and the buzzy device. The children in the buzzy experimental group will be connected to the buzzy cold and vibration device at least 8-10 cm above the area to be treated (upper part of the left arm antecubital fossa) 5-10 seconds before starting the procedure and the prick test application will be started.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Before starting the prick procedure, the children in the control group determined by randomisation will be given routine explanations according to the outpatient clinic procedure before starting the procedure and the prick test will be applied.
Study: NCT06676748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzydamine Hydrochloride
Description: The Difflam Forte Anti-Inflammatory Throat Spray (iNova Pharmaceuticals Pte Ltd, Singapore) is an over-the-counter medication indicated for temporary relief of painful mouth and throat conditions. It contains benzydamine hydrochloride (BH) 3 mg/mL, a non-steroidal anti-inflammatory agent (NSAID), and is recommended for adults to spray 2 to 4 times to the affected throat every 1.5 to 3 hours as needed.
Study: NCT06302309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: The intervention consists of four sessions of a 'managing the mental state' intervention, of which the first and second session will take place in the home-setting of the patient; the two remaining sessions will take place remotely. The sessions include psychoeducation on what anxiety is and how stress and anxiety can influence FOG, identifying how people are allocating attention and engage in specific thought-processes (e.g. worrisome thoughts) during walking, and educating patients about 'managing the mental state' compensation strategies that involve ways to reduce anxiety or stress and will be specifically tailored to the individual patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: The intervention consists of four sessions of a 'managing the mental state' intervention, of which the first and second session will take place in the home-setting of the patient; the two remaining sessions will take place remotely. The sessions include psychoeducation on what anxiety is and how stress and anxiety can influence FOG, identifying how people are allocating attention and engage in specific thought-processes (e.g. worrisome thoughts) during walking, and educating patients about 'managing the mental state' compensation strategies that involve ways to reduce anxiety or stress and will be specifically tailored to the individual patient.
Study: NCT06351592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-SOD
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-SOD
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-SOD
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-SOD
Description: Administered by intrathecal (IT) injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Administered by IT injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Administered by IT injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Administered by IT injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Administered by IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by IT injection
Study: NCT04719988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A total of 9 EDTA (ethylenediaminetetraacetic acid) tubes will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: Two 4 ml EDTA tube should be frozen in each investigation center for ctDNA collection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: A tumor biopsy will be performed at 2 months after enrollment.